SK bioscience's Covid-19 vaccine added to WHO EUL
Published: 20 Jun. 2023, 15:44
Updated: 20 Jun. 2023, 17:22
SK bioscience’s SKYCovione, Korea’s first domestically developed Covid-19 vaccine, was listed for emergency use by the World Health Organization (WHO).
The WHO Emergence Use Listing (EUL) is "a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the availability of those products to people affected by a public health emergency," according to WHO.
SK bioscience said the vaccines will be especially helpful for people in developing countries as they can be stored in normal refrigerators at 2 to 8 degrees Celsius unlike Moderna and Pfizer vaccines, which use mRNA (messenger ribonucleic acid) technology and require extremely low temperatures to remain effective.
SKYCovione received approval from a British regulator in May, becoming the first homegrown vaccine to gain sales approval in a foreign country.
“Based on the immunogenicity and safety profile, SKYCovione has become the first Korean vaccine to be put on the WHO EUL," said Ahn Jae-yong, SK bioscience CEO.
"We will be committed to developing more vaccines to not just strengthen Korea's vaccine sovereignty, but also to enable equitable access of the vaccine.”
BY SHIN HA-NEE [[email protected]]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)